Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study

Table 2 Genotypic resistance tests at failure according to treatment groups.

Patient	Group	NRTIs	Retrotranscriptase	Protease
1	Naïve patients	ABV + 3TC		10I, L63P
2		TDF + FTC	M184V	L63P
3		TDF + FTC	M184V	L63P, M46I, F53L
4	Restarting ART	ABV + 3TC		10I, 63P
5		TDF + ddI	M184V	D30N
6		AZT + ddI	K103N	V77I
7		TDF + FTC	K70R, T215F, 219Q	L63P
8		ZDV + TDF	M41L, D67N, K70R, L210W, T215Y	E35D, M36I, F53L, D60E, L63P, A71V, I84V
9	Previous failure	ZDV + TDF	L215Y

In 2 additional patients a wild type virus was observed. NRTIs: nucleos(t)ide reverse transcriptase inhibitors administered together with ritonavir-boosted saquinavir (1500/100 mg once daily). ABV: abacavir, ddI: didanosine, 3TC: lamivudine, FTC: emtricitabine, TDF: tenofovir, ZDV:zidovudine.

ISSN: 1742-6405